UDCA and Zinc as Adjuncts to Phototherapy : Shortening Treatment Time for Neonatal Hyperbilirubinemia- A Randomised Controlled Trial

Efficacy of ursodeoxycholic acid (UDCA) versus zinc supplementation in reducing phototherapy duration in neonates with unconjugated hyperbilirubinemia: A Randomised controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/112185

Enrollment

120

Registered

2026-06-08

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P588- Neonatal jaundice due to other specified excessive hemolysis

Interventions

Intervention1: Ursodeoxycholic Acid: Ursodeoxycholic Acid Drug Will Be Given To Neonates Receiving Phototherapy For Unconjugated Hyperbilirubinemia . Fall Of Bilirubin Level Will Be Studied at

Eligibility

Inclusion criteria

Inclusion criteria: Term neonates (more than equal to 37 weeks)

Exclusion criteria

Exclusion criteria: Conjugated Hyperbilirubemia Hemolytic Disease Sepsis ,Congenital Anomalies and Cholestasis Prior IVIG,Exchange Transfusion

Design outcomes

Primary

Measure	Time frame
Duration of phototherapy(hours) Rate of bilirubin decline(mg/dl/hour)Timepoint: at baseline ,12 hours and 24 hours	—

Secondary

Measure	Time frame
length of hospital stay( hours) Need for escalation(IVIG,exchange transfusion) Rebound hyperbilirubinemia(need for re-illumination) Adverse drug events( GI upset,abnormal LFTs if persistent symptoms)Timepoint: at baseline ,12 hours ,24 hours	—

Countries

India

Contacts

Public ContactHemant Kumar Chauhan

Jnmch Amu Aligarh

Druzmafirdaus@gmail.com9837122711

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026